Peter S. Rabinovitch
Uses mouse models to study how improving mitochondrial function changes lifespan and healthspan, including catalase-overexpressing mice and the drug elamipretide (SS-31)
Professor Emeritus, Laboratory Medicine and Pathology, University of Washington · Joint member, Fred Hutchinson Cancer Research Center · Fellow of the AAAS
Portrait: University of Washington Department of Laboratory Medicine and Pathology
JOH2013 is a Nature review by Simon Johnson, Peter Rabinovitch and Matt Kaeberlein, all at the University of Washington. It argues that mTOR is a leading target for slowing ageing: inhibiting the pathway extends lifespan in model organisms and protects against a growing list of age-related diseases. The authors also note that approved mTOR inhibitors exist, but that side effects currently rule out use in otherwise healthy people.
Rabinovitch joined the University of Washington Department of Pathology in 1992 and became a joint member of the Fred Hutchinson Cancer Research Center in 1998. His own laboratory works on mitochondria and ageing in mice, including animals that make extra catalase in their mitochondria and treatment with the peptide elamipretide, and on how mitochondrial energy production interacts with cell signalling.
His honours include election as a Fellow of the AAAS and the Denham Harman Lifetime Achievement in Research Award of the American Aging Association. He is now Professor Emeritus.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2013 | R | mTOR is a key modulator of ageing and age-related disease JOH2013 Middle author of the Nature review that presents mTOR inhibition as a route to slowing ageing and age-related disease. |
Co-authors in the Atlas 2
People with a profile here who share at least one study with Peter S. Rabinovitch.
ShowHide
- Matt Kaeberlein Extended TOR/aging research from yeast to mice to pet dogs
- Simon C. Johnson Biologist of aging and mitochondrial disease, first author with Peter Rabinovitch and Matt Kaeberlein of the 2013 Nature review that made the case for mTOR as a central controller of aging, now a professor at Northumbria University
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.